XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.22.1

Licensed rights and other intangible assets | 12 Months Ended
--- | ---
Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract] |
Licensed rights and other intangible assets |
6. | Licensed rights and other intangible assets
The following provides information about our license rights and other intangible assets, net (in thousands):
|  | As of December 31, 2021 |  |  | As of December 31, 2020 |
|  | Gross |  |  |  |  |  |  |  |  |  |  | Gross |  |  |  |  |  |  |  |  |
|  | Carrying |  |  | Accumulated |  |  |  |  |  |  | Carrying |  |  | Accumulated |  |  |  |  |
|  | Amount |  |  | Amortization |  |  | Net |  |  | Amount |  |  | Amortization |  |  | Net |
License rights and other intangible assets subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License rights |  | $ | 40,000 |  |  | $ | 6,826 |  |  | $ | 33,174 |  |  | $ | 40,000 |  |  | $ | 3,803 |  |  | $ | 36,197 |
Hormone therapy drug patents |  |  | 5,834 |  |  |  | 1,042 |  |  |  | 4,792 |  |  |  | 4,045 |  |  |  | 749 |  |  |  | 3,296 |
Hormone therapy drug patents applied and pending approval |  |  | 2,020 |  |  |  | — |  |  |  | 2,020 |  |  |  | 1,629 |  |  |  | — |  |  |  | 1,629 |
License rights and other intangible assets subject to amortization |  |  | 47,854 |  |  |  | 7,868 |  |  |  | 39,986 |  |  |  | 45,674 |  |  |  | 4,552 |  |  |  | 41,122 |
Intangible assets not subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks/trade name rights |  |  | 332 |  |  |  | — |  |  |  | 332 |  |  |  | 323 |  |  |  | — |  |  |  | 323 |
License rights and other intangible assets, net |  | $ | 48,186 |  |  | $ | 7,868 |  |  | $ | 40,318 |  |  | $ | 45,997 |  |  | $ | 4,552 |  |  | $ | 41,445 |
We recorded amortization expense related to the exclusive license rights agreement with Population Council of $3.0 million for 2021 and 2020, and $0.8 million for 2019. We recorded amortization expense related to patents of $0.3 million for 2021 and 2020, and $0.2 million for 2019. Our license rights and other intangible assets subject to amortization is expected to be amortized as follows (in thousands):
Year ending December 31, |
2022 |  | $ | 3,451 |
2023 |  |  | 3,445 |
2024 |  |  | 3,447 |
2025 |  |  | 3,445 |
2026 |  |  | 3,445 |
Thereafter |  |  | 20,733 |
Total |  | $ | 37,966 |
We use a combination of qualitative and quantitative factors to assess licensed rights and intangible assets for impairment. As a result of performing these assessments, we determined that no impairment existed as of December 31, 2021, therefore, no write downs were recorded to our licensed rights and other intangible assets for 2021. For 2020 and 2019, we wrote off $1.1 million and $0.1 million, respectively, in costs related to patents and trademarks, which were included in general and administrative expenses in the accompanying consolidated statements of operations.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration